The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Dec. 19, 2006

Filed:

Oct. 30, 2000
Applicants:

David H. Lynch, Bainbridge Island, WA (US);

Kenneth A. Brasel, Seattle, WA (US);

Hilary J. Mckenna, Seattle, WA (US);

Luis G. Borges, Seattle, WA (US);

Charles R. Maliszewski, Seattle, WA (US);

Eugene Maraskovsky, Victoria, AU;

Inventors:

David H. Lynch, Bainbridge Island, WA (US);

Kenneth A. Brasel, Seattle, WA (US);

Hilary J. McKenna, Seattle, WA (US);

Luis G. Borges, Seattle, WA (US);

Charles R. Maliszewski, Seattle, WA (US);

Eugene Maraskovsky, Victoria, AU;

Assignee:

Innunex Corporation, Seattle, WA (US);

Attorney:
Primary Examiner:
Int. Cl.
CPC ...
C12N 5/02 (2006.01); C12N 5/06 (2006.01); C12N 5/08 (2006.01);
U.S. Cl.
CPC ...
Abstract

Flt3-ligand can be used to generate large numbers of dendritic cells from hematopoietic progenitor and stem cells. Flt3-ligand can be used to augment immune responses in vivo, and expand dendritic cells ex vivo. Such dendritic cells can then be used to present tumor, viral or other antigens to naive T cells, can be useful as vaccine adjuvants. When flt3-L is used and/or administered in combination with other reactive agents, e.g. CD40 binding proteins and 4-1BBL or antibodies reactive with 4-1BB, the combination further enhances immune responses and the effectiveness of vaccine adjuvants.


Find Patent Forward Citations

Loading…